Social anxiety disorder, also called social phobia, is an anxiety disorder characterized by marked fear of negative evaluation in social situations and avoidance or endurance of those situations with distress.
Ask a research question about Social Anxiety Disorder. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
Conditions with similar clinical presentations that must be differentiated from Social Anxiety Disorder:
name: Social Anxiety Disorder
creation_date: "2026-04-24T20:56:38Z"
updated_date: "2026-05-02T00:00:00Z"
category: Psychiatric
description: >-
Social anxiety disorder, also called social phobia, is an anxiety disorder
characterized by marked fear of negative evaluation in social situations and
avoidance or endurance of those situations with distress.
disease_term:
preferred_term: social anxiety disorder
term:
id: MONDO:0001247
label: social phobia
parents:
- Anxiety Disorder
- Mental Health Disorder
pathophysiology:
- name: Early Life Adversity Risk
description: >-
Early life adversity is represented as an upstream environmental risk
factor for adult social anxiety disorder.
downstream:
- target: Immune-Related Signal Transduction Changes
description: >-
Early adversity is modeled upstream of long-lasting gene-expression and
immune-related signal-transduction changes.
evidence:
- reference: DOI:10.3389/fpsyt.2023.1125553
reference_title: Blood transcriptome analysis suggests an indirect molecular association of early life adversities and adult social anxiety disorder by immune-related signal transduction
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
One of the main risk factors for SAD is stress, especially during early
periods of life (early life adversity; ELA).
explanation: >-
Transcriptome study background supports ELA as an environmental risk
factor.
- reference: PMID:18374843
reference_title: Social anxiety disorder.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Social anxiety disorder is the most common anxiety disorder; it has an
early age of onset--by age 11 years in about 50% and by age 20 years in
about 80% of individuals
explanation: >-
Lancet review documents very early onset of SAD, consistent with
developmental risk factors including early life adversity.
- name: Social Fear and Avoidance Circuitry
description: >-
The core clinical mechanism is severe fear in social situations and
avoidance of scrutiny or negative evaluation.
cell_types:
- preferred_term: neuron
term:
id: CL:0000540
label: neuron
locations:
- preferred_term: amygdala
term:
id: UBERON:0001876
label: amygdala
- preferred_term: prefrontal cortex
term:
id: UBERON:0000451
label: prefrontal cortex
downstream:
- target: Social Anxiety
description: >-
Social fear circuitry is modeled as the proximal source of social
anxiety symptoms.
evidence:
- reference: DOI:10.3389/fpsyt.2023.1125553
reference_title: Blood transcriptome analysis suggests an indirect molecular association of early life adversities and adult social anxiety disorder by immune-related signal transduction
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Social anxiety disorder (SAD) is a psychiatric disorder characterized by
severe fear in social situations and avoidance of these.
explanation: >-
The study provides a concise clinical mechanism statement.
- reference: PMID:18374843
reference_title: Social anxiety disorder.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Functional neuroimaging studies point to increased activity in amygdala
and insula in patients with social anxiety disorder
explanation: >-
Lancet review confirms amygdala and insula hyperactivation as
neurobiological underpinning of SAD.
- reference: PMID:30155657
reference_title: "Neuroimaging Predictors and Mechanisms of Treatment Response in Social Anxiety Disorder: an Overview of the Amygdala."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Aberrant amygdala activity is implicated in the neurobiology of social
anxiety disorder (SAD) and is, therefore, a treatment target.
explanation: >-
Neuroimaging review confirms aberrant amygdala activity in SAD
neurobiology.
- reference: PMID:19935490
reference_title: "Social anxiety disorder: epidemiology, biology and treatment."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Functional magnetic resonance imaging studies have repeatedly emphasized
the central role of the amygdalae and insula in the neural circuitry of
the disorder.
explanation: >-
Review confirms central role of amygdala and insula in SAD neural
circuitry.
- name: Immune-Related Signal Transduction Changes
description: >-
Peripheral blood RNA-seq findings implicate MAPK3 expression, signal
transduction pathways, and inflammatory responses in SAD and ELA-related
biology.
biological_processes:
- preferred_term: signal transduction
term:
id: GO:0007165
label: signal transduction
modifier: ABNORMAL
- preferred_term: inflammatory response
term:
id: GO:0006954
label: inflammatory response
modifier: ABNORMAL
evidence:
- reference: DOI:10.3389/fpsyt.2023.1125553
reference_title: Blood transcriptome analysis suggests an indirect molecular association of early life adversities and adult social anxiety disorder by immune-related signal transduction
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Gene functional enrichment analyses indicate a role of signal
transduction pathways as well as inflammatory responses supporting an
involvement of the immune system in the association of ELA and SAD.
explanation: >-
RNA-seq enrichment supports signal-transduction and inflammatory response
nodes.
- name: Epigenetic Methylation Differences
description: >-
EWAS data identify social-anxiety-associated differentially methylated
regions and ELA-related methylation findings, indicating epigenetic
correlates of SAD and adversity.
downstream:
- target: Immune-Related Signal Transduction Changes
description: >-
Epigenetic differences are modeled upstream of longer-term molecular
regulation changes.
evidence:
- reference: DOI:10.1038/s41398-021-01225-w
reference_title: DNA methylation differences associated with social anxiety disorder and early life adversity
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We identified two differentially methylated regions (DMRs) associated
with SAD located within the genesSLC43A2andTNXB.
explanation: >-
EWAS supports SAD-associated methylation differences.
- name: Cognitive-Behavioral Maintenance Processes
description: >-
Cognitive models of social anxiety emphasize modifiable maintenance
processes such as self-focused attention, safety behaviors, avoidance, and
distorted social-threat appraisals that sustain fear of negative
evaluation.
downstream:
- target: Social Anxiety
description: >-
Cognitive-behavioral maintenance processes are represented as upstream
contributors to persistent social anxiety symptoms.
evidence:
- reference: DOI:10.1017/s0033291722002008
reference_title: "More than doubling the clinical benefit of each hour of therapist time: a randomised controlled trial of internet cognitive therapy for social anxiety disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Mediation analysis indicated that change in process variables specified
in cognitive models accounted for 60% of the improvements associated with
either treatment.
explanation: >-
RCT supports cognitive-model process variables as treatment mechanisms.
- reference: PMID:18374843
reference_title: Social anxiety disorder.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
A range of effective cognitive behavioural and pharmacological treatments
for children and adults now exists; the challenges lie in optimum
integration and dissemination of these treatments, and learning how to
help the 30-40% of patients for whom treatment does not work.
explanation: >-
Lancet review supports cognitive behavioral approaches while noting
that 30-40% of patients do not respond to treatment.
phenotypes:
- name: Social Anxiety
category: Behavioral
description: Marked anxiety in social situations involving scrutiny.
phenotype_term:
preferred_term: Social anxiety
term:
id: HP:6000029
label: Social anxiety
evidence:
- reference: clinicaltrials:NCT04879641
reference_title: "Optimizing Cognitive-behavioral Therapy for Social Anxiety Disorder Using the Factorial Design: What Works Best and How Does it Work (OPTIMIZE)"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Social Anxiety Disorder (SAD) is characterized by a marked fear of
negative evaluation in social situations.
explanation: >-
Trial record defines the core social-anxiety phenotype.
- reference: PMID:36573969
reference_title: "Anxiety Disorders: A Review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
social anxiety disorder (13% lifetime prevalence)
explanation: >-
JAMA review reports 13% lifetime prevalence of social anxiety disorder,
confirming it as a highly prevalent phenotype.
- name: Fear of Negative Evaluation
category: Behavioral
description: Fear of negative evaluation in social situations is a core SAD symptom.
phenotype_term:
preferred_term: Fear of negative evaluation
evidence:
- reference: clinicaltrials:NCT04879641
reference_title: "Optimizing Cognitive-behavioral Therapy for Social Anxiety Disorder Using the Factorial Design: What Works Best and How Does it Work (OPTIMIZE)"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Social Anxiety Disorder (SAD) is characterized by a marked fear of
negative evaluation in social situations.
explanation: >-
ClinicalTrials.gov record directly supports fear of negative evaluation
as a defining SAD symptom.
- name: Social Withdrawal
category: Behavioral
description: Avoidance or withdrawal from social situations is central to SAD.
phenotype_term:
preferred_term: Social withdrawal
evidence:
- reference: DOI:10.3389/fpsyt.2023.1125553
reference_title: Blood transcriptome analysis suggests an indirect molecular association of early life adversities and adult social anxiety disorder by immune-related signal transduction
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Social anxiety disorder (SAD) is a psychiatric disorder characterized by
severe fear in social situations and avoidance of these.
explanation: >-
The study definition supports avoidance of social situations as a core
SAD behavioral phenotype.
- name: Performance Anxiety
category: Behavioral
description: Performance-related social anxiety can impair work or role functioning.
phenotype_term:
preferred_term: Performance anxiety
evidence:
- reference: DOI:10.48101/ujms.v128.9289
reference_title: "Stand-alone virtual reality exposure therapy as a treatment for social anxiety symptoms: a systematic review and meta-analysis"
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
Social anxiety is common and can have far-reaching implications for
affected individuals, both on social life and working performance.
explanation: >-
Systematic review supports performance-related impairment in social
anxiety; performance-anxiety subtype status is clinical.
- name: Anxiety
category: Behavioral
description: General anxiety symptoms may accompany SAD and are monitored in trials.
phenotype_term:
preferred_term: Anxiety
term:
id: HP:0000739
label: Anxiety
evidence:
- reference: DOI:10.1017/s0033291722002008
reference_title: "More than doubling the clinical benefit of each hour of therapist time: a randomised controlled trial of internet cognitive therapy for social anxiety disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Secondary outcomes included disability, general anxiety, depression and a
behaviour test.
explanation: >-
RCT documents general anxiety as a measured outcome.
- name: Depression
category: Behavioral
description: Depression symptoms are common secondary outcomes and comorbid concerns.
phenotype_term:
preferred_term: Depression
term:
id: HP:0000716
label: Depression
evidence:
- reference: DOI:10.1017/s0033291722002008
reference_title: "More than doubling the clinical benefit of each hour of therapist time: a randomised controlled trial of internet cognitive therapy for social anxiety disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Secondary outcomes included disability, general anxiety, depression and a
behaviour test.
explanation: >-
RCT documents depression as a secondary outcome.
- reference: PMID:18374843
reference_title: Social anxiety disorder.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
it is a risk factor for subsequent depressive illness and substance abuse
explanation: >-
Lancet review identifies SAD as a risk factor for subsequent depression.
- name: Suicidal Ideation
category: Behavioral
description: Youth social anxiety is associated with suicidality in meta-analysis.
phenotype_term:
preferred_term: Suicidal ideation
term:
id: HP:0031589
label: Suicidal ideation
evidence:
- reference: DOI:10.1007/s10802-022-00996-0
reference_title: "Social Anxiety and Suicidality in Youth: A Systematic Review and Meta-analysis"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
social anxiety was associated cross-sectionally with suicide attempt (r =
0.10, 95% CI: 0.04, 0.15), suicidal ideation (r = 0.22, 95% CI: 0.02,
0.41), and suicide risk (r = 0.24, 95% CI: 0.05, 0.41),
explanation: >-
Meta-analysis supports suicidality association.
- name: Palpitations
category: Autonomic
description: >-
Palpitations are a common autonomic physical symptom experienced during
social anxiety episodes.
phenotype_term:
preferred_term: Palpitations
term:
id: HP:0001962
label: Palpitations
evidence:
- reference: PMID:36573969
reference_title: "Anxiety Disorders: A Review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Anxiety disorders are associated with physical symptoms, such as
palpitations, shortness of breath, and dizziness.
explanation: >-
JAMA review documents palpitations as a physical symptom associated
with anxiety disorders including SAD.
- name: Abnormal Fear-Induced Behavior
category: Behavioral
description: >-
Abnormal fear responses in social situations, including avoidance
behaviors and anticipatory anxiety, are core features of SAD.
phenotype_term:
preferred_term: Abnormal fear-induced behavior
term:
id: HP:0100852
label: Abnormal fear-induced behavior
evidence:
- reference: PMID:36573969
reference_title: "Anxiety Disorders: A Review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Anxiety disorders are characterized by symptoms that include worry,
social and performance fears, unexpected and/or triggered panic attacks,
anticipatory anxiety, and avoidance behaviors.
explanation: >-
JAMA review describes social and performance fears and avoidance
behaviors as characteristic symptoms of anxiety disorders.
- reference: PMID:19935490
reference_title: "Social anxiety disorder: epidemiology, biology and treatment."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The disease places a massive burden on patients lives, affecting not
only their social interactions but also their educational and
professional activities, thereby constituting a severe disability.
explanation: >-
Review confirms that fear-induced avoidance and disability extend to
educational and professional domains.
- name: Dyspnea
category: Autonomic
description: >-
Shortness of breath is a physical symptom associated with anxiety
disorders including social anxiety disorder.
phenotype_term:
preferred_term: Shortness of breath
term:
id: HP:0002094
label: Dyspnea
evidence:
- reference: PMID:36573969
reference_title: "Anxiety Disorders: A Review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Anxiety disorders are associated with physical symptoms, such as
palpitations, shortness of breath, and dizziness.
explanation: >-
JAMA review documents shortness of breath as a physical symptom
associated with anxiety disorders including SAD.
- name: Vertigo
category: Autonomic
description: >-
Vertigo or dizziness is a physical symptom associated with anxiety
disorders including social anxiety disorder.
phenotype_term:
preferred_term: Vertigo
term:
id: HP:0002321
label: Vertigo
evidence:
- reference: PMID:36573969
reference_title: "Anxiety Disorders: A Review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Anxiety disorders are associated with physical symptoms, such as
palpitations, shortness of breath, and dizziness.
explanation: >-
JAMA review documents dizziness as a physical symptom associated
with anxiety disorders including SAD.
diagnosis:
- name: Clinical social-anxiety assessment
presence: >-
Diagnosis is clinical and based on fear of negative evaluation, avoidance
or distress in social situations, persistence, impairment, and differential
assessment.
diagnosis_term:
preferred_term: clinical assessment
term:
id: MAXO:0000487
label: clinical assessment
evidence:
- reference: clinicaltrials:NCT04879641
reference_title: "Optimizing Cognitive-behavioral Therapy for Social Anxiety Disorder Using the Factorial Design: What Works Best and How Does it Work (OPTIMIZE)"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Social Anxiety Disorder (SAD) is characterized by a marked fear of
negative evaluation in social situations.
explanation: >-
Trial record supports the central diagnostic symptom.
- name: Structured interviews and severity scales
presence: >-
ADIS/SCID interviews and composite social anxiety scales are used in
trials; registry diagnoses have acceptable positive predictive value.
diagnosis_term:
preferred_term: clinical assessment
term:
id: MAXO:0000487
label: clinical assessment
evidence:
- reference: DOI:10.1186/s12888-020-02644-7
reference_title: Validity and reliability of social anxiety disorder diagnoses in the Swedish National Patient Register
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Of these, 77 files (81.05%) were considered to be ‘true positive’ cases
(PPV = 0.81, 95% confidence interval = 0.72–0.88).
explanation: >-
Register validation supports diagnostic validity of recorded SAD
diagnoses.
- name: Biomarkers remain investigational
presence: >-
Transcriptomic and methylation findings are research signals and not
stand-alone diagnostic tests.
diagnosis_term:
preferred_term: clinical assessment
term:
id: MAXO:0000487
label: clinical assessment
evidence:
- reference: DOI:10.3389/fpsyt.2023.1125553
reference_title: Blood transcriptome analysis suggests an indirect molecular association of early life adversities and adult social anxiety disorder by immune-related signal transduction
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In conclusion, we did not identify a direct molecular link between ELA
and adult SAD by transcriptional changes.
explanation: >-
RNA-seq study cautions against a direct diagnostic molecular link.
differential_diagnoses:
- name: Agoraphobia
description: >-
Agoraphobia involves fear or avoidance of places where escape or help may
be difficult, rather than negative social evaluation.
disease_term:
preferred_term: agoraphobia
term:
id: MONDO:0003709
label: agoraphobia
evidence:
- reference: clinicaltrials:NCT04879641
reference_title: "Optimizing Cognitive-behavioral Therapy for Social Anxiety Disorder Using the Factorial Design: What Works Best and How Does it Work (OPTIMIZE)"
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
a marked fear of negative evaluation in social situations.
explanation: >-
Social-evaluation fear helps distinguish SAD from agoraphobia.
- name: Panic disorder
description: Panic disorder is centered on recurrent unexpected panic attacks.
disease_term:
preferred_term: panic disorder
term:
id: MONDO:0005383
label: panic disorder
evidence:
- reference: clinicaltrials:NCT04879641
reference_title: "Optimizing Cognitive-behavioral Therapy for Social Anxiety Disorder Using the Factorial Design: What Works Best and How Does it Work (OPTIMIZE)"
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
a marked fear of negative evaluation in social situations.
explanation: >-
Negative evaluation fear distinguishes SAD from panic-centered
presentations.
- name: Generalized anxiety disorder
description: GAD involves broad persistent worry rather than social-evaluation fear.
disease_term:
preferred_term: generalized anxiety disorder
term:
id: MONDO:0001942
label: generalized anxiety disorder
evidence:
- reference: DOI:10.1017/s0033291722002008
reference_title: "More than doubling the clinical benefit of each hour of therapist time: a randomised controlled trial of internet cognitive therapy for social anxiety disorder"
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
Secondary outcomes included disability, general anxiety, depression and a
behaviour test.
explanation: >-
RCT measures general anxiety separately from social anxiety.
- name: Autism spectrum disorder
description: >-
Autism can include social avoidance or difficulty but is distinguished by
developmental social-communication differences and restricted/repetitive
behaviors.
disease_term:
preferred_term: autism spectrum disorder
term:
id: MONDO:0005258
label: autism spectrum disorder
evidence:
- reference: DOI:10.1186/s12888-020-02644-7
reference_title: Validity and reliability of social anxiety disorder diagnoses in the Swedish National Patient Register
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
two independent raters reviewed each file to assess the presence or
absence of SAD
explanation: >-
Chart review supports diagnostic confirmation; ASD is a clinical
differential for social impairment.
treatments:
- name: Cognitive behavioral therapy and CT-SAD
description: >-
Disorder-specific CBT, including face-to-face CT-SAD and internet-delivered
iCT-SAD, is an evidence-supported psychotherapy for adult social anxiety
disorder.
treatment_term:
preferred_term: cognitive behavior therapy
term:
id: MAXO:0000883
label: cognitive behavior therapy
target_phenotypes:
- preferred_term: Social anxiety
term:
id: HP:6000029
label: Social anxiety
- preferred_term: Fear of negative evaluation
evidence:
- reference: DOI:10.1017/s0033291722002008
reference_title: "More than doubling the clinical benefit of each hour of therapist time: a randomised controlled trial of internet cognitive therapy for social anxiety disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
CT-SAD and iCT-SAD were both superior to WAIT on all measures.
explanation: >-
RCT supports both face-to-face cognitive therapy and internet cognitive
therapy for social anxiety disorder.
- reference: DOI:10.1002/npr2.12365
reference_title: "Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology: Clinical practice guideline for social anxiety disorder (2021)"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Summarized recommendations for social anxiety disorder in adults are
selective serotonin reuptake inhibitors and serotonin‐norepinephrine
reuptake inhibitor for CQ1, cognitive behavioral therapy for CQ2, and
there are no recommendations regarding monotherapy and combination
therapy for CQ3.
explanation: >-
Clinical practice guideline recommends CBT as the adult SAD psychotherapy
option.
- reference: PMID:36573969
reference_title: "Anxiety Disorders: A Review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Cognitive behavioral therapy is the psychotherapy with the most evidence of
efficacy for anxiety disorders compared with psychological or pill placebo
explanation: >-
JAMA review confirms CBT as the most evidence-based psychotherapy for
anxiety disorders including SAD.
- name: SSRI pharmacotherapy
description: >-
SSRI pharmacotherapy is recommended for adult social anxiety disorder, with
sertraline and paroxetine represented as class examples.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: sertraline
term:
id: CHEBI:9123
label: sertraline
- preferred_term: paroxetine
term:
id: CHEBI:7936
label: paroxetine
target_phenotypes:
- preferred_term: Social anxiety
term:
id: HP:6000029
label: Social anxiety
evidence:
- reference: DOI:10.1002/npr2.12365
reference_title: "Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology: Clinical practice guideline for social anxiety disorder (2021)"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Summarized recommendations for social anxiety disorder in adults are
selective serotonin reuptake inhibitors and serotonin‐norepinephrine
reuptake inhibitor for CQ1, cognitive behavioral therapy for CQ2, and
there are no recommendations regarding monotherapy and combination
therapy for CQ3.
explanation: >-
Clinical practice guideline supports SSRI pharmacotherapy for adult SAD.
- reference: PMID:36573969
reference_title: "Anxiety Disorders: A Review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Selective serotonin reuptake inhibitors (SSRIs, eg, sertraline) and
serotonin-norepinephrine reuptake inhibitors (SNRIs, eg, venlafaxine
extended release) remain first-line pharmacotherapy for generalized anxiety
disorder, social anxiety disorder, and panic disorder.
explanation: >-
JAMA review confirms SSRIs as first-line pharmacotherapy for SAD.
- reference: DOI:10.1017/S1092852924000142
reference_title: "Trajectory and magnitude of response in adults with anxiety disorders: a Bayesian hierarchical modeling meta-analysis of selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and benzodiazepines"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Across 122 trials (N=15,760), SSRIs, SNRIs, and benzodiazepines produced
significant improvement in anxiety compared to placebo.
explanation: >-
Meta-analysis supports SSRI efficacy across adult anxiety-disorder trials,
including social anxiety disorder trials.
- name: SNRI pharmacotherapy
description: >-
SNRI pharmacotherapy is recommended for adult social anxiety disorder, with
venlafaxine represented as a class example.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: venlafaxine
term:
id: CHEBI:9943
label: venlafaxine
target_phenotypes:
- preferred_term: Social anxiety
term:
id: HP:6000029
label: Social anxiety
evidence:
- reference: DOI:10.1002/npr2.12365
reference_title: "Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology: Clinical practice guideline for social anxiety disorder (2021)"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Summarized recommendations for social anxiety disorder in adults are
selective serotonin reuptake inhibitors and serotonin‐norepinephrine
reuptake inhibitor for CQ1, cognitive behavioral therapy for CQ2, and
there are no recommendations regarding monotherapy and combination
therapy for CQ3.
explanation: >-
Clinical practice guideline supports SNRI pharmacotherapy for adult SAD.
- reference: DOI:10.1017/S1092852924000142
reference_title: "Trajectory and magnitude of response in adults with anxiety disorders: a Bayesian hierarchical modeling meta-analysis of selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and benzodiazepines"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Across 122 trials (N=15,760), SSRIs, SNRIs, and benzodiazepines produced
significant improvement in anxiety compared to placebo.
explanation: >-
Meta-analysis supports SNRI efficacy across adult anxiety-disorder trials,
including social anxiety disorder trials.
- name: Virtual reality exposure therapy
description: >-
Stand-alone virtual reality exposure therapy is an emerging exposure-based
treatment for social anxiety symptoms, with preliminary meta-analytic
evidence but uncertainty from few studies and high risk of bias.
treatment_term:
preferred_term: virtual reality exposure therapy
target_phenotypes:
- preferred_term: Social anxiety
term:
id: HP:6000029
label: Social anxiety
- preferred_term: Fear of negative evaluation
evidence:
- reference: DOI:10.48101/ujms.v128.9289
reference_title: "Stand-alone virtual reality exposure therapy as a treatment for social anxiety symptoms: a systematic review and meta-analysis"
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
VRET resulted in a significantly lower anxiety score in treated
individuals with a standard mean difference of −0.82, 95% confidence
interval –1.52 to –0.13, compared to controls.
explanation: >-
Meta-analysis supports reduced anxiety scores after VRET, but the
evidence is marked partial because the abstract notes few studies and
high risk of bias.
clinical_trials:
- name: NCT04879641
phase: NOT_APPLICABLE
status: COMPLETED
description: Factorial optimization trial of internet-based CBT components for SAD.
target_phenotypes:
- preferred_term: Social anxiety
term:
id: HP:6000029
label: Social anxiety
evidence:
- reference: clinicaltrials:NCT04879641
reference_title: "Optimizing Cognitive-behavioral Therapy for Social Anxiety Disorder Using the Factorial Design: What Works Best and How Does it Work (OPTIMIZE)"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
to investigate the active ingredients of ICBT for SAD by testing the main
effects and interactions for the four main treatment components
explanation: >-
ClinicalTrials.gov record documents ICBT component testing.
- name: NCT03346239
phase: NOT_APPLICABLE
status: COMPLETED
description: Trial comparing attention training, SSRIs, and waitlist in social anxiety.
target_phenotypes:
- preferred_term: Social anxiety
term:
id: HP:6000029
label: Social anxiety
evidence:
- reference: clinicaltrials:NCT03346239
reference_title: Effect of Attention Training or SSRIs on Symptoms and Neural Activation in Social Anxiety
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The purpose of this study is to determine the clinical efficacy and
neuro-cognitive mechanisms of Gaze-Contingent Usic Reward Therapy for
social anxiety disorder, compared with treatment with SSRIs or waitlist
control.
explanation: >-
ClinicalTrials.gov record documents attention training and SSRI
comparison.
- name: NCT00434759
phase: NOT_APPLICABLE
status: COMPLETED
description: Stepped-care computer-based self-help trial for social phobia.
target_phenotypes:
- preferred_term: Social anxiety
term:
id: HP:6000029
label: Social anxiety
evidence:
- reference: clinicaltrials:NCT00434759
reference_title: "Evaluation of the Efficacy, Mechanisms of Change and Efficiency of a Stepped-care Program With a Computer-based Self-help Module and Minimal Therapist Contact in Comparison to a Standard Cognitive Therapy for Patients With Social Phobia"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The purpose of this study is to examine efficacy and efficiency of a
Stepped Care Program (SCP) for patients with Social Phobia in comparison
to the standard cognitive therapy for Social Phobia according to D.M.
Clark.
explanation: >-
ClinicalTrials.gov record documents stepped-care treatment for social
phobia.
datasets:
- accession: DOI:10.1186/s12888-020-02644-7
title: Validity and reliability of social anxiety disorder diagnoses in the Swedish National Patient Register
description: Swedish register validation study of recorded SAD diagnoses.
organism:
preferred_term: Homo sapiens
term:
id: NCBITaxon:9606
label: Homo sapiens
sample_count: 95
conditions:
- social anxiety disorder
publication: DOI:10.1186/s12888-020-02644-7
evidence:
- reference: DOI:10.1186/s12888-020-02644-7
reference_title: Validity and reliability of social anxiety disorder diagnoses in the Swedish National Patient Register
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
After exclusion of files not containing sufficient information, 95 files
were included in the analyses.
explanation: >-
Abstract reports validation sample.
findings:
- statement: SAD register diagnoses had PPV 0.81 and substantial inter-rater agreement.
evidence:
- reference: DOI:10.1186/s12888-020-02644-7
reference_title: Validity and reliability of social anxiety disorder diagnoses in the Swedish National Patient Register
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Inter-rater agreement regarding the presence or absence of SAD was
substantial (κ = 0.72).
explanation: >-
Captures diagnostic reliability.
- accession: DOI:10.1017/s0033291722002008
title: "More than doubling the clinical benefit of each hour of therapist time: a randomised controlled trial of internet cognitive therapy for social anxiety disorder"
description: RCT comparing internet cognitive therapy, face-to-face CT-SAD, and waitlist.
organism:
preferred_term: Homo sapiens
term:
id: NCBITaxon:9606
label: Homo sapiens
sample_count: 102
conditions:
- social anxiety disorder
publication: DOI:10.1017/s0033291722002008
evidence:
- reference: DOI:10.1017/s0033291722002008
reference_title: "More than doubling the clinical benefit of each hour of therapist time: a randomised controlled trial of internet cognitive therapy for social anxiety disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
102 patients with social anxiety disorder were randomised to iCT-SAD,
CT-SAD, or waitlist (WAIT) control
explanation: >-
Abstract reports RCT sample and arms.
findings:
- statement: Internet CT-SAD matched face-to-face CT-SAD on primary outcome with less therapist time.
evidence:
- reference: DOI:10.1017/s0033291722002008
reference_title: "More than doubling the clinical benefit of each hour of therapist time: a randomised controlled trial of internet cognitive therapy for social anxiety disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
iCT-SAD did not differ from CT-SAD on the primary outcome at
post-treatment or follow-up.
explanation: >-
Captures the main comparative efficacy result.
- accession: DOI:10.3389/fpsyt.2023.1125553
title: Blood transcriptome analysis suggests an indirect molecular association of early life adversities and adult social anxiety disorder by immune-related signal transduction
description: Peripheral blood RNA-seq study of SAD and ELA groups.
organism:
preferred_term: Homo sapiens
term:
id: NCBITaxon:9606
label: Homo sapiens
conditions:
- social anxiety disorder
- early life adversity
publication: DOI:10.3389/fpsyt.2023.1125553
evidence:
- reference: DOI:10.3389/fpsyt.2023.1125553
reference_title: Blood transcriptome analysis suggests an indirect molecular association of early life adversities and adult social anxiety disorder by immune-related signal transduction
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Therefore, we conducted a transcriptome study of SAD and ELA performing
RNA sequencing in peripheral blood samples.
explanation: >-
Abstract documents the dataset modality.
findings:
- statement: Thirteen SAD-associated DEGs were identified, with MAPK3 most significant and immune-related signal transduction implicated.
evidence:
- reference: DOI:10.3389/fpsyt.2023.1125553
reference_title: Blood transcriptome analysis suggests an indirect molecular association of early life adversities and adult social anxiety disorder by immune-related signal transduction
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
13 significantly differentially expressed genes (DEGs) were identified
with respect to SAD
explanation: >-
Captures the transcriptome result.
notes: >-
Mechanisms are separated into early adversity, social fear/avoidance,
immune-related signal transduction, methylation, and cognitive-behavioral
maintenance processes with downstream links.
Social Anxiety Disorder is characterized by persistent fear and avoidance of social situations driven by concerns about negative evaluation (e.g., humiliation, rejection), producing clinically significant impairment in daily functioning. A recent expert review defines SAD as “persistent anxiety or avoidance of social situations because of a fear of negative evaluation.” (wolitzkytaylor2023recentadvancesin pages 1-3)
SAD is widely described as multifactorial, involving both genetic and environmental contributors. A transcriptome study states: “Multiple genetic as well as environmental factors contribute to the etiopathology of SAD.” (edelmann2023bloodtranscriptomeanalysis pages 1-2)
A 2024 genetics-focused chapter summarizes family and twin evidence indicating that SAD “runs in families,” including findings that risk increases with genetic relatedness and that partners of affected individuals are about four times more likely to have SAD—interpreted as consistent with assortative mating. (bashoogendam2024geneticvulnerabilityto pages 1-6)
Twin evidence summarized in the same chapter reports a meta-analytic estimate that genetic factors explain ~0.41 of variance in social anxiety, while non-shared environmental factors explain ~0.54 (shared environment less prominent). (bashoogendam2024geneticvulnerabilityto pages 1-6)
Gap: SAD-specific GWAS loci / polygenic risk scores were not available in the retrieved full texts.
Early-life stress/adversity is repeatedly highlighted as a major environmental risk factor for later SAD. The blood transcriptome study states: “One of the main risk factors for SAD is stress, especially during early periods of life (early life adversity; ELA).” (edelmann2023bloodtranscriptomeanalysis pages 1-2)
Direct protective factors specific to SAD were not identified in the retrieved corpus. (gap)
A 2021 EWAS identified SAD-associated differentially methylated regions (DMRs) in SLC43A2 and TNXB, with mean methylation differences reported on the order of ~9.3% and 5.3% across sites, respectively. (wiegand2021dnamethylationdifferences pages 3-6)
The same study identified ELA-associated DMRs in the SLC17A3 promoter and SIAH3, with mean methylation differences ~8.7% and 10.6%, and multiple DMRs associated with SAD×ELA interaction, including regions in C2CD2L and MRPL28 showing among the largest methylation differences. (wiegand2021dnamethylationdifferences pages 3-6)
Commonly emphasized phenotypes include: - fear of negative evaluation and humiliation; - avoidance of social situations; - performance/public-speaking anxiety; - functional impairment in work and social life. (wolitzkytaylor2023recentadvancesin pages 1-3, clark2023morethandoubling pages 1-2, rejbrand2023standalonevirtualreality pages 1-2)
The retrieved sources do not provide canonical HPO mappings; below are suggested phenotype anchors consistent with the measures and constructs explicitly used: - Social withdrawal (HPO: HP:0000726) (conceptual alignment with avoidance/withdrawal) (wolitzkytaylor2023recentadvancesin pages 1-3) - Anxiety (HPO: HP:0000739) (clark2023morethandoubling pages 4-5) - Performance anxiety (mapped to performance-only subtype discussed in DSM-5 context in VRET review) (rejbrand2023standalonevirtualreality pages 1-2) - Fear of negative evaluation (anchored to FNE scale used in SAD trials) (clark2023morethandoubling pages 4-5)
(Additional phenotype/HPO suggestions are summarized in the structured table artifact.)
SAD is associated with substantial impairment. In Swedish registry validation, reviewed cases were described as in the moderate range of severity and functional impairment using CGI-S and GAF in chart review. (vilaplanaperez2020validityandreliability pages 1-2)
No single causal gene is established in the retrieved sources; evidence supports polygenic/multifactorial liability. (bashoogendam2024geneticvulnerabilityto pages 1-6)
A 2023 peripheral blood RNA-seq study found 13 differentially expressed genes (DEGs) associated with SAD, with MAPK3 reported as the most significantly expressed gene (upregulated in SAD; p=0.003 in the abstract). Functional enrichment implicated “signal transduction pathways” and “inflammatory responses,” supporting immune-system involvement in the association between ELA and SAD, but concluded no direct transcriptional mediation of ELA→SAD. (edelmann2023bloodtranscriptomeanalysis pages 1-2)
Network enrichment and interactome analysis highlighted immune-related signal transduction and MAPK/STAT involvement, including STAT3, RAF1, and PTPN7 as relevant to MAPK3-linked immune signaling. (edelmann2023bloodtranscriptomeanalysis pages 6-7)
See Section 2.4 for EWAS results (SLC43A2, TNXB; and ELA-linked DMRs). (wiegand2021dnamethylationdifferences pages 3-6)
The retrieved sources emphasize psychosocial stress/ELA as a major environmental factor and a mechanistic driver via immune dysregulation and long-lasting gene-expression regulation. (edelmann2023bloodtranscriptomeanalysis pages 1-2)
A key contemporary mechanistic framing is the cognitive model of social phobia (Clark & Wells), operationalized in CT-SAD interventions; targeted maintenance processes include self-focused attention, safety behaviors, distorted self-imagery, and trauma-related social memories. The iCT-SAD RCT describes a protocol implementing these components (e.g., video feedback, behavioral experiments, discrimination training/memory rescripting for early socially traumatic memories). (clark2023morethandoubling pages 2-4)
The blood transcriptome study frames ELA as producing “structural and regulatory alterations,” including immune dysregulation, and reports signal transduction and inflammatory enrichment; MAPK3 upregulation is highlighted, with network-level links to JAK–STAT/interleukin-related signaling modules in ELA. (edelmann2023bloodtranscriptomeanalysis pages 1-2, edelmann2023bloodtranscriptomeanalysis pages 6-7)
The WFSBP guideline notes that despite extensive neurobiology research, “no biomarker has to date proven sufficiently sensitive and specific.” (bandelow2023worldfederationof pages 16-20)
Direct SAD-specific neuroimaging anatomical conclusions were not available in the retrieved corpus. Evidence for anxiety disorders more broadly (not SAD-specific) suggests brain structure/function involvement; however, this is not used here as a SAD-specific anatomical claim. (zanoaga2024brainwidemendelianrandomization pages 1-4)
Mean age of onset for SAD is reported as 14.3 years in a guideline synthesis referencing a meta-analysis across representative surveys. (bandelow2023worldfederationof pages 16-20)
SAD is repeatedly described as persistent/chronic and impairing; an RCT background notes it is among the most persistent common mental health problems without treatment, and a 2023 review highlights early onset and persistent course. (wolitzkytaylor2023recentadvancesin pages 1-3, clark2023morethandoubling pages 1-2)
Swedish NPR context: 31,975 SAD cases were recorded from 1997–2013; annual incidence increased sharply after 2001 due to outpatient data inclusion. (vilaplanaperez2020validityandreliability pages 2-5)
Evidence supports polygenic/multifactorial inheritance (familial aggregation + heritability), rather than Mendelian inheritance. (bashoogendam2024geneticvulnerabilityto pages 1-6)
In the iCT-SAD RCT, diagnostic assessment used structured clinical interviews including the SAD module of the ADIS and screening modules of SCID-I and SCID-II (with additional modules as indicated). (clark2023morethandoubling pages 2-4)
Swedish NPR ICD-10 SAD coding validation: among 95 analyzable medical files, 77 were true positives, PPV 0.81 (95% CI 0.72–0.88), with substantial inter-rater agreement (κ 0.72). (vilaplanaperez2020validityandreliability pages 1-2)
Trials also used general measures such as GAD-7 and PHQ-9 to track anxious/depressed mood and risk. (clark2023morethandoubling pages 4-5)
SAD is associated with substantial functional impairment and persistence; additionally, suicidality links in youth are supported by a 2023 systematic review/meta-analysis showing cross-sectional associations between social anxiety and suicide attempt (r=0.10), suicidal ideation (r=0.22), and suicide risk (r=0.24). (leigh2023socialanxietyand pages 1-2)
A 2023 adult guideline for SAD in Japan suggests disorder-specific CBT (Clark & Wells or Heimberg models) delivered individually by a skilled therapist (weak recommendation; low certainty), and suggests supported CBT self-help when face-to-face CBT is declined. (asakura2023japanesesocietyof pages 1-2)
A randomized controlled trial compared face-to-face CT-SAD vs internet-delivered CT-SAD with remote therapist support. - Sample: 102 patients randomized. - Efficacy: iCT-SAD did not differ from CT-SAD on the primary outcome at post-treatment or follow-up. - Efficiency: Total therapist time was 6.45 h for iCT-SAD vs 15.8 h for CT-SAD for the same reduction in social anxiety. - Mechanistic mediation: change in process variables specified in cognitive models accounted for 60% of improvements. This supports scalable implementation (increasing benefit per therapist-hour). (clark2023morethandoubling pages 1-2)
A 2023 systematic review/meta-analysis of stand-alone VRET for social anxiety symptoms (PROSPERO CRD42022361900; published 14 Sep 2023) reported: - Included studies: 5 studies in the primary meta-analysis - Effect: standardized mean difference SMD −0.82 (95% CI −1.52 to −0.13) vs controls - Caveat: few studies, small samples, and high risk of bias. (rejbrand2023standalonevirtualreality pages 1-2, rejbrand2023standalonevirtualreality pages 4-6)
Forest-plot visual evidence for the VRET effect is provided in the extracted figure images. (rejbrand2023standalonevirtualreality media f192a911, rejbrand2023standalonevirtualreality media 5bbbb219)
Japanese guideline suggests: - SSRIs (weak; low certainty) - Venlafaxine (SNRI) (weak; low certainty) and does not recommend for/against monotherapy vs combination due to insufficient evidence. (asakura2023japanesesocietyof pages 1-2)
A 2024 Bayesian hierarchical meta-analysis across anxiety disorders (122 trials; N=15,760) found SSRIs, SNRIs, and benzodiazepines all produced significant improvement vs placebo; benzodiazepines produced faster improvement by week 1, but by week 8 outcomes did not differ significantly between classes; placebo response plateaued by week 4 and social anxiety disorder trials had lower placebo response at week 8 than other anxiety disorders. (mendez2024trajectoryandmagnitude pages 1-2)
Direct SAD-specific prevention trials were not retrieved; however, multiple sources emphasize early onset, chronicity, and under-recognition/access barriers, supporting: - Secondary prevention: early detection/screening and early intervention (especially youth), consistent with guideline emphasis on treatment indication and scalability via internet delivery. (bandelow2023worldfederationof pages 16-20, clark2023morethandoubling pages 1-2) - Tertiary prevention: relapse/nonresponse monitoring; comorbidity management (depression, suicidality), consistent with youth suicidality association evidence. (leigh2023socialanxietyand pages 1-2)
No naturally occurring SAD-equivalent diagnosis in non-human species was retrieved; however, translational fear/avoidance phenotypes are modeled experimentally in rodents (see below). (toth2012socialfearconditioning pages 1-2)
A 2012 Neuropsychopharmacology study developed a social fear conditioning mouse paradigm as a “novel and specific animal model to study social anxiety disorder,” in which electric foot shocks are paired with investigation of a conspecific, reducing investigation of unfamiliar conspecifics both short- and long-term and producing social-stimulus-specific fear without generalized anxiety/depression/locomotor impairment. (toth2012socialfearconditioning pages 1-2)
The induced social fear was reversed by acute diazepam (dose-dependent) and by chronic paroxetine, supporting predictive validity for medications used clinically in SAD. (toth2012socialfearconditioning pages 1-2, toth2012socialfearconditioning pages 9-10)
The SFC paradigm supports studying extinction-like processes analogous to exposure-based CBT (repeated social stimulus exposure reduces fear) and enables testing fast-acting vs delayed-onset medications. Limitations include model specificity to conditioned social fear and historical rather than 2023–2024 development. (toth2012socialfearconditioning pages 9-10)
Key 2023–2024 advancements captured in the retrieved evidence include: 1) guideline updates emphasizing CBT and SSRI/SNRI first-line approaches (Japan guideline 2023; WFSBP guideline 2023), (asakura2023japanesesocietyof pages 1-2, bandelow2023worldfederationof pages 16-20) 2) scalable digital implementation evidence (iCT-SAD RCT, published 2023), (clark2023morethandoubling pages 1-2) 3) synthesis of stand-alone VRET outcomes (meta-analysis published 2023) with supporting forest-plot evidence, (rejbrand2023standalonevirtualreality pages 1-2, rejbrand2023standalonevirtualreality media f192a911) 4) quantitative meta-analytic modeling of pharmacotherapy response trajectories across anxiety disorders (2024). (mendez2024trajectoryandmagnitude pages 1-2)
The following artifact consolidates identifiers, definitions, epidemiology, risk factors, phenotypes/HPO suggestions, diagnostics, mechanisms, and treatments with quantitative data and direct URLs.
| Claim/Item | Key quantitative data | Evidence type | Source (journal/year) | DOI/URL | Context citation |
|---|---|---|---|---|---|
| Disease name and synonym | Social anxiety disorder (SAD), also called social phobia | Disease definition / registry validation | BMC Psychiatry / 2020 | https://doi.org/10.1186/s12888-020-02644-7 | (vilaplanaperez2020validityandreliability pages 1-2, vilaplanaperez2020validityandreliability pages 2-5) |
| Core definition | “Persistent anxiety or avoidance of social situations because of a fear of negative evaluation” | Expert review | Faculty Reviews / 2023 | https://doi.org/10.12703/r/12-8 | (wolitzkytaylor2023recentadvancesin pages 1-3) |
| ICD-10 identifier | ICD-10 code F40.1; ICD-10 uses the term “social phobia” | Administrative coding / diagnostic validity study | BMC Psychiatry / 2020 | https://doi.org/10.1186/s12888-020-02644-7 | (vilaplanaperez2020validityandreliability pages 2-5) |
| MeSH identifier | MeSH term used in the literature: “Phobia, Social” | Literature indexing evidence | Clinical Practice & Epidemiology in Mental Health / 2021 | https://doi.org/10.2174/1745017902117010224 | (alnemr2024prevalenceofsocial pages 19-20) |
| 12-month prevalence | Estimated U.S. 12-month prevalence about 8% | Expert review / epidemiology synthesis | Faculty Reviews / 2023 | https://doi.org/10.12703/r/12-8 | (wolitzkytaylor2023recentadvancesin pages 1-3) |
| Lifetime prevalence | Average worldwide lifetime prevalence about 4%; youth-oriented review cites lifetime prevalence about 11% | Epidemiology review / systematic review | BMC Psychiatry / 2020; Research on Child and Adolescent Psychopathology / 2023 | https://doi.org/10.1186/s12888-020-02644-7; https://doi.org/10.1007/s10802-022-00996-0 | (vilaplanaperez2020validityandreliability pages 1-2, leigh2023socialanxietyand pages 1-2) |
| Typical age of onset | Mean age of onset for SAD 14.3 years | Guideline evidence synthesis | World Journal of Biological Psychiatry / 2023 | https://doi.org/10.1080/15622975.2022.2086295 | (bandelow2023worldfederationof pages 16-20) |
| Sex ratio | Female:male ratio for SAD about 1.2–2.1 | Guideline evidence synthesis | World Journal of Biological Psychiatry / 2023 | https://doi.org/10.1080/15622975.2022.2086295 | (bandelow2023worldfederationof pages 16-20) |
| Typical clinical cohort age | Mean age of SAD participants in clinical studies 35.2 years | Guideline evidence synthesis | World Journal of Biological Psychiatry / 2023 | https://doi.org/10.1080/15622975.2022.2086295 | (bandelow2023worldfederationof pages 16-20) |
| Chronicity / course | Described as early onset, persistent/chronic, and highly impairing if untreated | Expert review / RCT background | Faculty Reviews / 2023; Psychological Medicine / 2023 | https://doi.org/10.12703/r/12-8; https://doi.org/10.1017/S0033291722002008 | (wolitzkytaylor2023recentadvancesin pages 1-3, clark2023morethandoubling pages 1-2) |
| Familial aggregation | In a multigenerational study, first-degree relatives had higher risk than second- and third-degree relatives; partners were about 4× more likely to have SAD than partners of controls | Family study review | Current Topics in Behavioral Neurosciences / 2024 | https://doi.org/10.1007/7854_2024_544 | (bashoogendam2024geneticvulnerabilityto pages 1-6) |
| Heritability / genetics | Twin meta-analysis estimate for social anxiety variance due to genetics about 0.41; non-shared environment about 0.54 | Twin-study review | Current Topics in Behavioral Neurosciences / 2024 | https://doi.org/10.1007/7854_2024_544 | (bashoogendam2024geneticvulnerabilityto pages 1-6) |
| Environmental risk factor | Early life adversity (ELA) is described as a major environmental risk factor for SAD | Human molecular / epigenetic / transcriptomic evidence | Translational Psychiatry / 2021; Frontiers in Psychiatry / 2023 | https://doi.org/10.1038/s41398-021-01225-w; https://doi.org/10.3389/fpsyt.2023.1125553 | (edelmann2023bloodtranscriptomeanalysis pages 1-2, wiegand2021dnamethylationdifferences pages 1-2) |
| Gene–environment / transcriptomic link | RNA-seq found 13 DEGs for SAD; MAPK3 was the most significantly expressed gene and was upregulated in SAD (p = 0.003); no direct ELA-related DEGs, suggesting an indirect link via immune-related signal transduction | Human transcriptomics | Frontiers in Psychiatry / 2023 | https://doi.org/10.3389/fpsyt.2023.1125553 | (edelmann2023bloodtranscriptomeanalysis pages 1-2, edelmann2023bloodtranscriptomeanalysis pages 6-7) |
| Immune-related mechanisms | ELA-associated co-expression modules were enriched for interleukin regulation/production, JAK-STAT signaling, and broader signal transduction; MAPK3 interactome highlighted STAT3, RAF1, PTPN7 | Human transcriptomics / network analysis | Frontiers in Psychiatry / 2023 | https://doi.org/10.3389/fpsyt.2023.1125553 | (edelmann2023bloodtranscriptomeanalysis pages 6-7) |
| Epigenetic findings: SAD-associated DMRs | First EWAS in SAD identified DMRs in SLC43A2 and TNXB; mean DNAm differences about 9.3% and 5.3% respectively | Human epigenome-wide association study | Translational Psychiatry / 2021 | https://doi.org/10.1038/s41398-021-01225-w | (wiegand2021dnamethylationdifferences pages 1-2, wiegand2021dnamethylationdifferences pages 3-6) |
| Epigenetic findings: ELA-associated DMRs | ELA-associated DMRs identified in SLC17A3 promoter and SIAH3 with mean DNAm differences about 8.7% and 10.6% | Human epigenome-wide association study | Translational Psychiatry / 2021 | https://doi.org/10.1038/s41398-021-01225-w | (wiegand2021dnamethylationdifferences pages 3-6) |
| Epigenetic interaction findings | SAD×ELA interaction DMRs included C2CD2L and MRPL28; methylation differences exceeded 9% and 6% in relevant subgroup contrasts | Human epigenome-wide association study | Translational Psychiatry / 2021 | https://doi.org/10.1038/s41398-021-01225-w | (wiegand2021dnamethylationdifferences pages 3-6) |
| Brain systems implicated in anxiety biology | Genetically inferred causal effects for anxiety involved reduced area/volume in right posterior middle-cingulate gyrus and right anterior superior temporal gyrus (beta about -0.09) | Human MR / imaging genetics (anxiety-disorder level, not SAD-specific) | medRxiv preprint / 2023 | https://doi.org/10.1101/2023.09.12.23295448 | (zanoaga2024brainwidemendelianrandomization pages 1-4) |
| Core phenotype: fear of negative evaluation | Suggested HPO: HP:0033676 Fear of negative evaluation | Symptom construct / scale domain | Psychological Medicine / 2023 | https://doi.org/10.1017/S0033291722002008 | (clark2023morethandoubling pages 4-5) |
| Core phenotype: social avoidance | Suggested HPO: HP:0000726 Social withdrawal | Symptom construct / definition | Faculty Reviews / 2023 | https://doi.org/10.12703/r/12-8 | (wolitzkytaylor2023recentadvancesin pages 1-3) |
| Core phenotype: performance/public-speaking anxiety | Suggested HPO: HP:0033672 Performance anxiety | Symptom construct / review | Upsala Journal of Medical Sciences / 2023 | https://doi.org/10.48101/ujms.v128.9289 | (rejbrand2023standalonevirtualreality pages 1-2) |
| Core phenotype: functional impairment | Suggested HPO: HP:0033677 Impaired social functioning | Clinical impact / registry validation | BMC Psychiatry / 2020 | https://doi.org/10.1186/s12888-020-02644-7 | (vilaplanaperez2020validityandreliability pages 1-2) |
| Core phenotype: anxious mood | Suggested HPO: HP:0000739 Anxiety | General symptom domain | Psychological Medicine / 2023 | https://doi.org/10.1017/S0033291722002008 | (clark2023morethandoubling pages 4-5) |
| Diagnostic instrument: LSAS | Included in primary SAD composite; used as preferred SAD scale in guideline meta-analyses | Clinician/self-report instrument | Psychological Medicine / 2023; WFSBP Guideline / 2023 | https://doi.org/10.1017/S0033291722002008; https://doi.org/10.1080/15622975.2022.2086295 | (clark2023morethandoubling pages 4-5, bandelow2023worldfederationof pages 16-20) |
| Diagnostic instrument: SPIN | Included in primary SAD outcome composite | Self-report instrument | Psychological Medicine / 2023 | https://doi.org/10.1017/S0033291722002008 | (clark2023morethandoubling pages 4-5) |
| Diagnostic instruments: SPS and SIAS | Used in SAD trials and screening; factorial trial used cut-offs SPS 22 and SIAS 33 for inclusion | Self-report instruments / trial implementation | ClinicalTrials.gov NCT04879641; Psychological Medicine / 2023 | https://clinicaltrials.gov/study/NCT04879641; https://doi.org/10.1017/S0033291722002008 | (NCT04879641 chunk 3, clark2023morethandoubling pages 4-5) |
| Diagnostic instrument: FNE | Fear of Negative Evaluation scale included in the primary outcome composite | Self-report instrument | Psychological Medicine / 2023 | https://doi.org/10.1017/S0033291722002008 | (clark2023morethandoubling pages 4-5) |
| Diagnostic interviews: ADIS / SCID | ADIS, SCID-I, and SCID-II used for structured diagnostic assessment in CT-SAD/iCT-SAD RCT | Structured diagnostic assessment | Psychological Medicine / 2023 | https://doi.org/10.1017/S0033291722002008 | (clark2023morethandoubling pages 2-4) |
| Registry diagnostic validity | Among 95 reviewed records, 77 were true positives; PPV 0.81 (95% CI 0.72–0.88); κ 0.72 | Registry validation / chart review | BMC Psychiatry / 2020 | https://doi.org/10.1186/s12888-020-02644-7 | (vilaplanaperez2020validityandreliability pages 1-2) |
| First-line psychotherapy | CBT is first-line; guideline suggests individual disorder-specific CBT over group CBT; supported self-help if face-to-face CBT is declined | Clinical guideline | Neuropsychopharmacology Reports / 2023 | https://doi.org/10.1002/npr2.12365 | (asakura2023japanesesocietyof pages 1-2) |
| CT-SAD effectiveness/application | NICE-recommended first-line individual cognitive therapy for SAD; standard protocol allowed up to 14 weekly 90-min sessions plus boosters | RCT / implementation | Psychological Medicine / 2023 | https://doi.org/10.1017/S0033291722002008 | (clark2023morethandoubling pages 1-2, clark2023morethandoubling pages 2-4) |
| Internet CT-SAD (iCT-SAD) comparative efficacy | 102 patients randomized; iCT-SAD and CT-SAD both superior to waitlist and did not differ on primary outcome at post-treatment/follow-up | Randomized controlled trial | Psychological Medicine / 2023 | https://doi.org/10.1017/S0033291722002008 | (clark2023morethandoubling pages 1-2) |
| Internet CT-SAD therapist-time efficiency | iCT-SAD total therapist time 6.45 h versus CT-SAD 15.8 h for the same reduction in social anxiety; therapist support up to week 14 about 6.8 h; live contact 4.1 h; average 21.7 behavioral experiments completed | Randomized controlled trial / implementation | Psychological Medicine / 2023 | https://doi.org/10.1017/S0033291722002008 | (clark2023morethandoubling pages 1-2, clark2023morethandoubling pages 4-5) |
| Virtual reality exposure therapy (VRET) | Stand-alone VRET reduced social anxiety symptoms versus controls with SMD -0.82 (95% CI -1.52 to -0.13); based on 5 studies, high risk of bias | Systematic review and meta-analysis | Upsala Journal of Medical Sciences / 2023 | https://doi.org/10.48101/ujms.v128.9289 | (rejbrand2023standalonevirtualreality pages 1-2, rejbrand2023standalonevirtualreality pages 4-6, rejbrand2023standalonevirtualreality media f192a911) |
| Pharmacotherapy guideline recommendation | SSRIs suggested; venlafaxine (SNRI) suggested; both recommendations graded 2C (weak / low certainty) | Clinical guideline | Neuropsychopharmacology Reports / 2023 | https://doi.org/10.1002/npr2.12365 | (asakura2023japanesesocietyof pages 1-2) |
| Anxiety-disorder medication trajectory | Across 122 trials (N=15,760), SSRIs, SNRIs, and benzodiazepines all outperformed placebo; benzodiazepines improved faster by week 1 (p < 0.001); by week 8 benzodiazepines, SSRIs, and SNRIs did not differ significantly; SAD trials showed lower placebo response at week 8 | Bayesian meta-analysis across anxiety disorders | CNS Spectrums / 2024 | https://doi.org/10.1017/S1092852924000142 | (mendez2024trajectoryandmagnitude pages 1-2) |
| Benzodiazepines role | No longer first-line; commonly used for acute episodic anxiety or adjunctively with SSRIs/SNRIs | Meta-analysis background / pharmacotherapy context | CNS Spectrums / 2024 | https://doi.org/10.1017/S1092852924000142 | (mendez2024trajectoryandmagnitude pages 1-2) |
| Suicidality association in youth | Social anxiety associated cross-sectionally with suicide attempt r = 0.10, suicidal ideation r = 0.22, suicide risk r = 0.24 | Systematic review and meta-analysis | Research on Child and Adolescent Psychopathology / 2023 | https://doi.org/10.1007/s10802-022-00996-0 | (leigh2023socialanxietyand pages 1-2) |
| Quality-of-life / educational burden | SAD associated with marked QoL impairment and reduced academic attainment; in a Swedish cohort, odds of finishing upper secondary education were aOR 0.19 and starting university aOR 0.47 | Population cohort study / review | Psychological Medicine / 2021; Clinical Practice & Epidemiology in Mental Health / 2021 | https://doi.org/10.1017/S0033291719003908; https://doi.org/10.2174/1745017902117010224 | (alnemr2024prevalenceofsocial pages 19-20) |
Table: This table compiles key identifiers, epidemiology, mechanisms, phenotypes, diagnostics, and treatment evidence for Social Anxiety Disorder using recent and authoritative sources. It is structured to support rapid knowledge-base entry and citation-backed clinical or translational review.
References
(wolitzkytaylor2023recentadvancesin pages 1-3): Kate Wolitzky-Taylor and Richard LeBeau. Recent advances in the understanding and psychological treatment of social anxiety disorder. Faculty reviews, 12:8, Apr 2023. URL: https://doi.org/10.12703/r/12-8, doi:10.12703/r/12-8. This article has 27 citations.
(vilaplanaperez2020validityandreliability pages 2-5): Alba Vilaplana-Pérez, Josef Isung, Sonja Krig, Sarah Vigerland, Maral Jolstedt, Johan Bjureberg, Jens Högström, Kayoko Isomura, Daniel Rautio, Eva Serlachius, Christian Rück, David Mataix-Cols, and Lorena Fernández de la Cruz. Validity and reliability of social anxiety disorder diagnoses in the swedish national patient register. BMC Psychiatry, May 2020. URL: https://doi.org/10.1186/s12888-020-02644-7, doi:10.1186/s12888-020-02644-7. This article has 30 citations and is from a domain leading peer-reviewed journal.
(alnemr2024prevalenceofsocial pages 19-20): Lujain Alnemr, Abdelaziz H. Salama, Salma Abdelrazek, Hussein Alfakeer, Mohamed Ali Alkhateeb, and Perihan Torun. Prevalence of social anxiety disorder and its associated factors among foreign-born undergraduate students in türkiye: a cross-sectional study. PLOS Global Public Health, Apr 2024. URL: https://doi.org/10.1371/journal.pgph.0003184, doi:10.1371/journal.pgph.0003184. This article has 14 citations and is from a peer-reviewed journal.
(bandelow2023worldfederationof pages 16-20): Borwin Bandelow, Christer Allgulander, David S. Baldwin, Daniel Lucas da Conceição Costa, Damiaan Denys, Nesrin Dilbaz, Katharina Domschke, Elias Eriksson, Naomi A. Fineberg, Josef Hättenschwiler, Eric Hollander, Hisanobu Kaiya, Tatiana Karavaeva, Siegfried Kasper, Martin Katzman, Yong-Ku Kim, Takeshi Inoue, Leslie Lim, Vasilios Masdrakis, José M. Menchón, Euripedes C. Miguel, Hans-Jürgen Möller, Antonio E. Nardi, Stefano Pallanti, Giampaolo Perna, Dan Rujescu, Vladan Starcevic, Dan J. Stein, Shih-Jen Tsai, Michael Van Ameringen, Anna Vasileva, Zhen Wang, and Joseph Zohar. World federation of societies of biological psychiatry (wfsbp) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – version 3. part i: anxiety disorders. The World Journal of Biological Psychiatry, 24:79-117, Jul 2023. URL: https://doi.org/10.1080/15622975.2022.2086295, doi:10.1080/15622975.2022.2086295. This article has 262 citations.
(clark2023morethandoubling pages 2-4): David M. Clark, Jennifer Wild, Emma Warnock-Parkes, Richard Stott, Nick Grey, Graham Thew, and Anke Ehlers. More than doubling the clinical benefit of each hour of therapist time: a randomised controlled trial of internet cognitive therapy for social anxiety disorder. Psychological Medicine, 53:5022-5032, Jul 2023. URL: https://doi.org/10.1017/s0033291722002008, doi:10.1017/s0033291722002008. This article has 80 citations and is from a highest quality peer-reviewed journal.
(vilaplanaperez2020validityandreliability pages 1-2): Alba Vilaplana-Pérez, Josef Isung, Sonja Krig, Sarah Vigerland, Maral Jolstedt, Johan Bjureberg, Jens Högström, Kayoko Isomura, Daniel Rautio, Eva Serlachius, Christian Rück, David Mataix-Cols, and Lorena Fernández de la Cruz. Validity and reliability of social anxiety disorder diagnoses in the swedish national patient register. BMC Psychiatry, May 2020. URL: https://doi.org/10.1186/s12888-020-02644-7, doi:10.1186/s12888-020-02644-7. This article has 30 citations and is from a domain leading peer-reviewed journal.
(asakura2023japanesesocietyof pages 1-2): Satoshi Asakura, Naoki Yoshinaga, Hisashi Yamada, Yutaka Fujii, Nobuyuki Mitsui, Yoshihiro Kanai, Takeshi Inoue, and Eiji Shimizu. Japanese society of anxiety and related disorders/japanese society of neuropsychopharmacology: clinical practice guideline for social anxiety disorder (2021). Neuropsychopharmacology Reports, 43:288-309, Aug 2023. URL: https://doi.org/10.1002/npr2.12365, doi:10.1002/npr2.12365. This article has 20 citations.
(rejbrand2023standalonevirtualreality pages 1-2): Christian Rejbrand, Brynjar Fure, and Karin Sonnby. Stand-alone virtual reality exposure therapy as a treatment for social anxiety symptoms: a systematic review and meta-analysis. Upsala Journal of Medical Sciences, Sep 2023. URL: https://doi.org/10.48101/ujms.v128.9289, doi:10.48101/ujms.v128.9289. This article has 10 citations and is from a peer-reviewed journal.
(edelmann2023bloodtranscriptomeanalysis pages 1-2): Susanne Edelmann, Ariane Wiegand, Thomas Hentrich, Sarah Pasche, Julia Maria Schulze-Hentrich, Matthias H. J. Munk, Andreas J. Fallgatter, Benjamin Kreifelts, and Vanessa Nieratschker. Blood transcriptome analysis suggests an indirect molecular association of early life adversities and adult social anxiety disorder by immune-related signal transduction. Frontiers in Psychiatry, Apr 2023. URL: https://doi.org/10.3389/fpsyt.2023.1125553, doi:10.3389/fpsyt.2023.1125553. This article has 13 citations.
(wiegand2021dnamethylationdifferences pages 1-2): Ariane Wiegand, Benjamin Kreifelts, Matthias H. J. Munk, Nadja Geiselhart, Katia E. Ramadori, Julia L. MacIsaac, Andreas J. Fallgatter, Michael S. Kobor, and Vanessa Nieratschker. Dna methylation differences associated with social anxiety disorder and early life adversity. Translational Psychiatry, Feb 2021. URL: https://doi.org/10.1038/s41398-021-01225-w, doi:10.1038/s41398-021-01225-w. This article has 57 citations and is from a peer-reviewed journal.
(bashoogendam2024geneticvulnerabilityto pages 1-6): Janna Marie Bas-Hoogendam. Genetic vulnerability to social anxiety disorder. Current topics in behavioral neurosciences, Nov 2024. URL: https://doi.org/10.1007/7854_2024_544, doi:10.1007/7854_2024_544. This article has 2 citations.
(wiegand2021dnamethylationdifferences pages 3-6): Ariane Wiegand, Benjamin Kreifelts, Matthias H. J. Munk, Nadja Geiselhart, Katia E. Ramadori, Julia L. MacIsaac, Andreas J. Fallgatter, Michael S. Kobor, and Vanessa Nieratschker. Dna methylation differences associated with social anxiety disorder and early life adversity. Translational Psychiatry, Feb 2021. URL: https://doi.org/10.1038/s41398-021-01225-w, doi:10.1038/s41398-021-01225-w. This article has 57 citations and is from a peer-reviewed journal.
(clark2023morethandoubling pages 1-2): David M. Clark, Jennifer Wild, Emma Warnock-Parkes, Richard Stott, Nick Grey, Graham Thew, and Anke Ehlers. More than doubling the clinical benefit of each hour of therapist time: a randomised controlled trial of internet cognitive therapy for social anxiety disorder. Psychological Medicine, 53:5022-5032, Jul 2023. URL: https://doi.org/10.1017/s0033291722002008, doi:10.1017/s0033291722002008. This article has 80 citations and is from a highest quality peer-reviewed journal.
(clark2023morethandoubling pages 4-5): David M. Clark, Jennifer Wild, Emma Warnock-Parkes, Richard Stott, Nick Grey, Graham Thew, and Anke Ehlers. More than doubling the clinical benefit of each hour of therapist time: a randomised controlled trial of internet cognitive therapy for social anxiety disorder. Psychological Medicine, 53:5022-5032, Jul 2023. URL: https://doi.org/10.1017/s0033291722002008, doi:10.1017/s0033291722002008. This article has 80 citations and is from a highest quality peer-reviewed journal.
(edelmann2023bloodtranscriptomeanalysis pages 6-7): Susanne Edelmann, Ariane Wiegand, Thomas Hentrich, Sarah Pasche, Julia Maria Schulze-Hentrich, Matthias H. J. Munk, Andreas J. Fallgatter, Benjamin Kreifelts, and Vanessa Nieratschker. Blood transcriptome analysis suggests an indirect molecular association of early life adversities and adult social anxiety disorder by immune-related signal transduction. Frontiers in Psychiatry, Apr 2023. URL: https://doi.org/10.3389/fpsyt.2023.1125553, doi:10.3389/fpsyt.2023.1125553. This article has 13 citations.
(zanoaga2024brainwidemendelianrandomization pages 1-4): Mihaela-Diana Zanoaga, Eleni Friligkou, Jun He, Gita A. Pathak, Dora Koller, Brenda Cabrera-Mendoza, Murray B. Stein, and Renato Polimanti. Brainwide mendelian randomization study of anxiety disorders and symptoms. Biological Psychiatry, 95:810-817, Apr 2024. URL: https://doi.org/10.1016/j.biopsych.2023.11.006, doi:10.1016/j.biopsych.2023.11.006. This article has 35 citations and is from a highest quality peer-reviewed journal.
(toth2012socialfearconditioning pages 1-2): Iulia Toth, Inga D Neumann, and David A Slattery. Social fear conditioning: a novel and specific animal model to study social anxiety disorder. Neuropsychopharmacology, 37:1433-1443, Jan 2012. URL: https://doi.org/10.1038/npp.2011.329, doi:10.1038/npp.2011.329. This article has 157 citations and is from a highest quality peer-reviewed journal.
(leigh2023socialanxietyand pages 1-2): Eleanor Leigh, Kenny Chiu, and Elizabeth D. Ballard. Social anxiety and suicidality in youth: a systematic review and meta-analysis. Research on Child and Adolescent Psychopathology, 51:441-454, Dec 2023. URL: https://doi.org/10.1007/s10802-022-00996-0, doi:10.1007/s10802-022-00996-0. This article has 54 citations and is from a domain leading peer-reviewed journal.
(rejbrand2023standalonevirtualreality pages 4-6): Christian Rejbrand, Brynjar Fure, and Karin Sonnby. Stand-alone virtual reality exposure therapy as a treatment for social anxiety symptoms: a systematic review and meta-analysis. Upsala Journal of Medical Sciences, Sep 2023. URL: https://doi.org/10.48101/ujms.v128.9289, doi:10.48101/ujms.v128.9289. This article has 10 citations and is from a peer-reviewed journal.
(rejbrand2023standalonevirtualreality media f192a911): Christian Rejbrand, Brynjar Fure, and Karin Sonnby. Stand-alone virtual reality exposure therapy as a treatment for social anxiety symptoms: a systematic review and meta-analysis. Upsala Journal of Medical Sciences, Sep 2023. URL: https://doi.org/10.48101/ujms.v128.9289, doi:10.48101/ujms.v128.9289. This article has 10 citations and is from a peer-reviewed journal.
(rejbrand2023standalonevirtualreality media 5bbbb219): Christian Rejbrand, Brynjar Fure, and Karin Sonnby. Stand-alone virtual reality exposure therapy as a treatment for social anxiety symptoms: a systematic review and meta-analysis. Upsala Journal of Medical Sciences, Sep 2023. URL: https://doi.org/10.48101/ujms.v128.9289, doi:10.48101/ujms.v128.9289. This article has 10 citations and is from a peer-reviewed journal.
(mendez2024trajectoryandmagnitude pages 1-2): Eric M. Mendez, Jeffrey A. Mills, Vikram Suresh, Julia N. Stimpfl, and Jeffrey R. Strawn. Trajectory and magnitude of response in adults with anxiety disorders: a bayesian hierarchical modeling meta-analysis of selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and benzodiazepines. CNS Spectrums, 29:187-196, Mar 2024. URL: https://doi.org/10.1017/s1092852924000142, doi:10.1017/s1092852924000142. This article has 13 citations and is from a peer-reviewed journal.
(toth2012socialfearconditioning pages 9-10): Iulia Toth, Inga D Neumann, and David A Slattery. Social fear conditioning: a novel and specific animal model to study social anxiety disorder. Neuropsychopharmacology, 37:1433-1443, Jan 2012. URL: https://doi.org/10.1038/npp.2011.329, doi:10.1038/npp.2011.329. This article has 157 citations and is from a highest quality peer-reviewed journal.
(NCT04879641 chunk 3): Optimizing Cognitive-behavioral Therapy for Social Anxiety Disorder Using the Factorial Design. University of Bern. 2021. ClinicalTrials.gov Identifier: NCT04879641